Table 1. mRNA vaccine effectiveness in the Finnish elderly aged 70+ years adjusted for age group, sex, presence of medical conditions, residence in Helsinki-Uusimaa hospital district and residence in long-term care.
| Laboratory-confirmed SARS-CoV-2 infection | Covid-19 hospitalisation | |||||
|---|---|---|---|---|---|---|
| Cases, n | Cumulative riska | Vaccine effectivenessb, % | Cases, n | Cumulative riska | Vaccine effectivenessb, % | |
| Not vaccinated | 1526 | 295 | Reference | 319 | 73 | Reference |
| First dose | ||||||
| 21–27 DSV | 71 | 349 | 41 (25–54) | 14 | 33 | 57 (24–75) |
| 28–34 DSV | 59 | 135 | 47 (30–59) | 13 | 28 | 59 (26–77) |
| 35–41 DSV | 56 | 233 | 46 (28–59) | 11 | 57 | 64 (32–81) |
| 42+ DSV | 197 | 104 | 46 (35–56) | 39 | 12 | 68 (50–79) |
| Second dose | ||||||
| 7+ DSV | 45 | 132 | 75 (65–82) | 2 | 3 | 93 (70–98) |
a Cumulative risk at the end of the study multiplied by 10000;
b Point estimate and 95% confidence interval; DSV, days since vaccination.